News Image

NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.

By Mill Chart

Last update: Dec 26, 2023

Consider GENMAB A/S -SP ADR (NASDAQ:GMAB) as an affordable growth stock, identified by our stock screening tool. NASDAQ:GMAB is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.

Growth Assessment of NASDAQ:GMAB

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:GMAB has received a 7 out of 10:

  • The Earnings Per Share has been growing by 36.32% on average over the past years. This is a very strong growth
  • Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 42.01%.
  • GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.90% yearly.
  • The Earnings Per Share is expected to grow by 19.39% on average over the next years. This is quite good.
  • Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 17.91% on average per year.

Valuation Assessment of NASDAQ:GMAB

ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:GMAB was assigned a score of 5 for valuation:

  • Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.49% of the companies listed in the same industry.
  • 96.66% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
  • Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaper than 95.66% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.16% of the companies listed in the same industry.
  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
  • GMAB's earnings are expected to grow with 15.11% in the coming years. This may justify a more expensive valuation.

Assessing Health Metrics for NASDAQ:GMAB

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:GMAB has earned a 8 out of 10:

  • An Altman-Z score of 23.03 indicates that GMAB is not in any danger for bankruptcy at the moment.
  • GMAB's Altman-Z score of 23.03 is amongst the best of the industry. GMAB outperforms 94.32% of its industry peers.
  • GMAB has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
  • The Debt to FCF ratio of GMAB (0.14) is better than 97.00% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • GMAB has a Current Ratio of 11.38. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB has a better Current ratio (11.38) than 80.47% of its industry peers.
  • A Quick Ratio of 11.36 indicates that GMAB has no problem at all paying its short term obligations.
  • GMAB's Quick ratio of 11.36 is amongst the best of the industry. GMAB outperforms 80.63% of its industry peers.

Assessing Profitability for NASDAQ:GMAB

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:

  • With an excellent Return On Assets value of 12.19%, GMAB belongs to the best of the industry, outperforming 97.83% of the companies in the same industry.
  • GMAB has a better Return On Equity (13.81%) than 96.66% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.04%, GMAB belongs to the best of the industry, outperforming 98.16% of the companies in the same industry.
  • GMAB had an Average Return On Invested Capital over the past 3 years of 17.24%. This is above the industry average of 13.03%.
  • GMAB's Profit Margin of 25.24% is amongst the best of the industry. GMAB outperforms 97.83% of its industry peers.
  • GMAB's Operating Margin of 37.10% is amongst the best of the industry. GMAB outperforms 98.50% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Check the latest full fundamental report of GMAB for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/23/2024, 4:01:25 PM)

After market: 29.0366 +0.48 (+1.67%)

28.56

-0.41 (-1.42%)

GMAB News

News Image12 days ago - ChartmillNASDAQ:GMAB is not too expensive for the growth it is showing.

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

News Image20 days ago - Investor's Business DailyGenmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image21 days ago - Genmab A/SGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
News Image2 months ago - Genmab A/SU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
News Image2 months ago - Seeking AlphaAbbVie/ Genmab win FDA priority review for lymphoma therapy (NYSE:ABBV)

Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.

News Image2 months ago - Seeking AlphaBMO upgrades Genmab to outperform, cites diversification potential (NASDAQ:GMAB)

BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term

News Image2 months ago - Seeking AlphaGenmab reports FY results (NASDAQ:GMAB)

Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...

News Image3 months ago - Seeking AlphaPfizer-Genmab cervical cancer drug gets accepted for EU review (NYSE:PFE)

Pfizer (PFE) and Genmab (GMAB) announced on Friday the marketing application for its cervical cancer antibody-drug conjugate ((ADC)) has been validated for revi

GMAB Links
Follow us for more